Ad
related to: does b12 interfere with levothyroxine treatment for osteoporosis icd 10
Search results
Results From The WOW.Com Content Network
Ipriflavone (INN, JAN; brand name Yambolap) is a synthetic isoflavone which may be used to inhibit bone resorption, [2] maintain bone density and to prevent osteoporosis in postmenopausal women. [1] It is not used to treat osteoporosis.
As a supplement it is used to treat vitamin B12 deficiency including pernicious anemia. [1] [2] Other uses include treatment for cyanide poisoning, Leber's optic atrophy, and toxic amblyopia. [3] [4] It is given by injection into a muscle or vein, [2] by pill or sublingually. Side effects are generally few. [2]
Treatment should take into account the cause and severity of the condition. [6] Treatment is done by vitamin B 12 supplementation, either by mouth or by injection. [3] Initially in high daily doses, followed by less frequent lower doses, as the condition improves. [3] If a reversible cause is found, that cause should be corrected if possible. [11]
Steroid-induced osteoporosis is osteoporosis arising from the use of glucocorticoids (a class of steroid hormones) analogous to Cushing's syndrome but involving mainly the axial skeleton. The synthetic glucocorticoid prescription drug prednisone is a main candidate after prolonged intake.
"B12" and "Cbl" redirect here. For other uses of B12, see B12 (disambiguation). For the musical group, see Carbon Based Lifeforms. Pharmaceutical compound Vitamin B12 General skeletal formula of cobalamins Stick model of cyanocobalamin (R = CN) based on the crystal structure Clinical data Other names Vitamin B12, vitamin B-12, cobalamin AHFS / Drugs.com Monograph MedlinePlus a605007 License ...
Bisphosphonates are recommended as a first line treatments for post-menopausal osteoporosis. [5] [10] [11] [12]Long-term treatment with bisphosphonates produces anti-fracture and bone mineral density effects that persist for 3–5 years after an initial 3–5 years of treatment. [2]
Treatment using oral drugs is an easier option in management but the bioavailability of B12 is low. This is due to low absorption in the intestine, and breakdown by enzyme activity. Research continues to focus on the use of permeation enhancers or permeation absorbers in combination with the treatment.
[10] [3] IL-1β has been shown to decrease liver D1, [10] as well as thyroid hormone receptor (THR) levels. IL-6 and TNFa downregulate D1 and suppress TSH, are negatively correlated with fT3, and are positively correlated with rT3. [3] NF-κB also inhibits D1, and decreases the expression of Thyroid receptors α and β. [3]